D D Breimer
Overview
Explore the profile of D D Breimer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
361
Citations
3678
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Gaillard P, Voorwinden L, Nielsen J, Ivanov A, Atsumi R, Engman H, et al.
Eur J Pharm Sci
. 2000 Dec;
12(3):215-22.
PMID: 11113640
Objective: The aim was to establish a flexible, abundantly available, reproducible and functionally characterized in vitro model of the blood-brain barrier (BBB). Methods: In a first step, bovine brain capillaries...
12.
de Lange E, De Boer A, Breimer D
Adv Drug Deliv Rev
. 2000 Dec;
45(2-3):125-48.
PMID: 11108971
Microdialysis is an in vivo technique that permits monitoring of local concentrations of drugs and metabolites at specific sites in the body. Microdialysis has several characteristics, which makes it an...
13.
van der Sandt I, De Boer A, Breimer D
Eur J Pharm Sci
. 2000 Oct;
11(3):207-14.
PMID: 11042226
The LLC-PK1:MDR1, LLC-PK1 and Caco-2 cell lines were used to investigate whether rhodamine-123 or doxorubicin would be the preferred substrate to study P-glycoprotein (P-gp) functionality in vitro. Both rhodamine-123 and...
14.
Hesselink M, Smolders H, De Boer A, Breimer D, Danysz W
Behav Pharmacol
. 2000 Apr;
10(1):85-98.
PMID: 10780305
Non-competitive N-methyl-D-aspartate (NMDA) receptor antagonists show antiparkinsonian-like activity in animal models, and possess neuroprotective properties. However they also induce a number of behavioral side effects in rodents at higher doses;...
15.
Pereira V, Auler Jr J, Carmona M, Mateus F, Lanchote V, Breimer D, et al.
Braz J Med Biol Res
. 2000 Apr;
33(5):509-14.
PMID: 10775881
We describe a new simple, selective and sensitive micromethod based on HPLC and fluorescence detection to measure debrisoquine (D) and 4-hydroxydebrisoquine (4-OHD) in urine for the investigation of xenobiotic metabolism...
16.
17.
Wijnholds J, deLange E, Scheffer G, Van Den Berg D, Mol C, van der Valk M, et al.
J Clin Invest
. 2000 Feb;
105(3):279-85.
PMID: 10675353
Multidrug resistance protein 1 (MRP1) is a transporter protein that helps to protect normal cells and tumor cells against the influx of certain xenobiotics. We previously showed that Mrp1 protects...
18.
Hesselink M, De Boer A, Breimer D, Danysz W
J Neural Transm (Vienna)
. 1999 Dec;
106(9-10):803-18.
PMID: 10599863
Memantine is an uncompetitive N-methyl-D-aspartate receptor antagonist which blocks the NMDA receptor with moderate-affinity in a use- and voltage dependent manner. In clinical practice it is used chronically in the...
19.
20.
Hesselink M, De Boer A, Breimer D, Danysz W
J Neural Transm (Vienna)
. 1999 Aug;
106(5-6):409-21.
PMID: 10443547
Behavioral changes have previously been reported following administrations of uncompetitive NMDA receptor antagonists memantine, amantadine and MK-801 for 14 days, at the doses that produce plasma levels comparable to those...